Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
166.31 ^USD	+0.01%		+0.49%	-2.17%

Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 13	Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM

Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial

Published on 01/06/2026 at 02:19 pm EST

Reuters

Latest news about Jazz Pharmaceuticals plc

Jan. 30	ALX Oncology Holdings Inc. Announces New Data from a Phase 1b/2 Clinical Trial Evaluating the Company's Investigational CD47-Inhibitor Evorpacept in Combination with Jazz Pharmaceuticals' ZIIHERTU	CI
Jan. 13	Jazz Pharmaceuticals plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
Jan. 12	Truist Raises Price Target on Jazz Pharmaceuticals to $230 From $220, Keeps Buy Rating	MT
Jan. 08	Jazz Pharmaceuticals Names Chief Business Officer	MT
Jan. 08	RBC Trims Price Target on Jazz Pharmaceuticals to $191 From $194, Keeps Outperform Rating	MT
Jan. 06	Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial	RE
Jan. 06	Zymeworks Inc. Announces Positive Efficacy and Safety Results from the Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera	CI
Dec. 10	This Is Decision Day
Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Dec. 09	Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing	MT
Dec. 02	Jazz Pharmaceuticals plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09:45 AM
Nov. 27	Saniona Reports Operating Profit of SEK 360 Million	FW
Nov. 24	Jazz Pharmaceuticals Insider Sold Shares Worth $607,127, According to a Recent SEC Filing	MT
Nov. 24	Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	MT
Nov. 20	Jazz Pharmaceuticals Insider Sold Shares Worth $1,204,573, According to a Recent SEC Filing	MT

Chart Jazz Pharmaceuticals plc

Duration

Period

JAZZ: Dynamic Chart

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâ€™s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Employees

2,800

Sector

Pharmaceuticals

Calendar

Feb. 24 - Q4 2025 Earnings Release

More about the company